These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18707880)

  • 1. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
    Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 7. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
    Santer R; Calado J
    Clin J Am Soc Nephrol; 2010 Jan; 5(1):133-41. PubMed ID: 19965550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
    Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
    Pajor AM; Randolph KM; Kerner SA; Smith CD
    J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
    J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats.
    Bickel M; Brummerhop H; Frick W; Glombik H; Herling AW; Heuer HO; Plettenburg O; Theis S; Werner U; Kramer W
    Arzneimittelforschung; 2008; 58(11):574-80. PubMed ID: 19137908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.
    Putapatri SR; Kanwal A; Banerjee SK; Kantevari S
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1528-31. PubMed ID: 24556379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2).
    van den Heuvel LP; Assink K; Willemsen M; Monnens L
    Hum Genet; 2002 Dec; 111(6):544-7. PubMed ID: 12436245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
    Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
    Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
    Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
    Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.